ADULT Updated: February 5, 2021

Regimen Reference Order - THOR - vinorelbine + CISplatin (MET)

ARIA: LUNG - [vinorelbine + CISplatin (MET)]

Planned Course: Every 28 days for 4 cycles

Indication for Use: Non-Small Cell Lung Cancer Metastatic

CVAD: Preferred (VESICANT INVOLVED)

Proceed with treatment if:

Day 1

• ANC equal to or greater than 1.5 x $10^{9}/L$ AND Platelets equal to or greater than $100 \times 10^{9}/L$

• Creatinine clearance greater than 45 mL/minute

Day 8

- ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$
 - Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
Not Applicable				

Treatment Regimen – THOR – vinorelbine + CISplatin (MET)

Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
Day 1				
magne sium sulfate	2 g	IV in normal saline 1000 mL over 2 hours (Pre hydration)		
aprepitant	125 mg	Orally 1 hour pre-chemotherapy		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy		
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy		
OLANZapine	2.5 mg	Orally 30 minutes pre-chemotherapy		
vinorelbine	30 mg/m ²	IV in normal saline 50 mL over 6 to 10 minutes by gravity infusion Slower or faster administration causes vein irritation Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability		
normal saline	125 mL	IV over 15 minutes *Nursing Alert: This volume is to be administered after standar flush		



CISplatin	75 mg/m ²	IV in normal saline 500 mL over 1 hour *Alert: CISplatin infusion must be complete prior to mannitol administration
mannitol	12.5 g	IV in normal saline 1000 mL over 2 hours (Post hydration)
Day 8		
Establish primary s	olution 500 mL of: norm	al saline
vinorelbine	30 mg/m ²	IV in normal saline 50 mL over 6 to 10 minutes by gravity infusion
		Slower or faster administration causes vein irritation
		Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability
normal saline	125 mL	IV over 15 minutes *Nursing Alert: This volume is to be administered after standard flush

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders
- Baseline blood pressure prior to magnesium infusion and repeat 15 minutes after start of magnesium infusion

Day8

• CBC

	Recommended Support Medications				
Drug	Dose	CCMB Administration Guideline			
aprepitant	80 mg	Orally once daily on Days 2 and 3			
dexamethasone	8 mg	Orally once daily on Days 2, 3 and 4			
OLANZapine	2.5 mg	Orally the evening of Day 1 then twice daily on Days 2, 3 and 4. Also use OLANZapine 2.5 to 5 mg AS NEEDED for breakthrough nausea and vomiting (including Days 1 to 4) up to a maximum of 10 mg per day. Contact clinic if nausea/vomiting is not adequately controlled			

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Instruct patient to notify clinic if having significant diarrheaor vomiting
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy



ADDITIONAL INFORMATION

- CISplatin is ototoxic and nephrotoxic
- CISplatin can cause hypomagnesemia

